Novel Approach to Amyloidosis Looks Promising MedPage Today "The ability of [the second-generation drug] to lower both mutant and nonmutant proteins may also provide a major advantage over liver transplantation, which affects the production of only mutant protein." Though it was a phase I, proof-of-principle ... Alnylam and Collaborators Publish Clinical Trial Results with RNAi ... |
